ReviewMobile DNA2025
A plan or pandemonium? The conundrum of retrotransposon activation in cancer.
Review in Mobile DNA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transcriptional Activation of Transposable Element (TE)-Associated Genes Is Frequently Associated with Altered Promoter Methylation in Placenta and Melanoma.International journal of molecular sciences · 2026Article
- Retroelement Hypomethylation Links Hypoxia Signaling, Immune Phenotypes, and Survival in Clear Cell Renal Cell Carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Correction: A plan or pandemonium? The conundrum of retrotransposon activation in cancer.Mobile DNA · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
Abstract
Cancer arises from a convergence of genetic mutations and epigenetic alterations. Among the consequences of epigenetic deregulation is the aberrant activation of transposable elements, particularly retrotransposons, the most expansive and functionally impactful class. This review examines the paradoxical role of retrotransposons in cancer, emphasizing their dual capacity to support oncogenesis while simultaneously triggering innate and adaptive immune responses that may limit tumor growth. A central question is discussed: Is retrotransposon activation merely a stochastic byproduct of epigenetic instability, or could it represent an intrinsic layer of early tumor surveillance that inadvertently turns against the host as malignancy progresses?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.